Citius Pharmaceuticals Inc
Company Profile
Business description
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Contact
11 Commerce Drive
First Floor
CranfordNJ07016
USAT: +1 908 967-6677
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2027
Employees
23
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,882.00 | 35.10 | -0.39% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 22,934.68 | 717.19 | -3.03% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,159.41 | 748.43 | -1.19% |
| NZX 50 Index | 13,709.78 | 37.06 | -0.27% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,768.30 | 24.90 | -0.28% |
| SSE Composite Index | 3,658.03 | 55.00 | -1.48% |